131 related articles for article (PubMed ID: 21817806)
21. Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial.
Miyauchi K; Kimura T; Shimokawa H; Daida H; Iimuro S; Iwata H; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Ohashi Y; Ohtsu H; Saito Y; Matsuzaki M; Nagai R;
Int Heart J; 2018 Mar; 59(2):315-320. PubMed ID: 29503404
[TBL] [Abstract][Full Text] [Related]
22. Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease.
Volis I; Saliba W; Jaffe R; Eitan A; Zafrir B
Am J Cardiol; 2020 Aug; 128():28-34. PubMed ID: 32650921
[TBL] [Abstract][Full Text] [Related]
23. Appropriate Level of Low-Density Lipoprotein Cholesterol for Secondary Prevention of Coronary Artery Disease.
Naito R; Miyauchi K; Konishi H; Tsuboi S; Ogita M; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Daida H
J Atheroscler Thromb; 2016; 23(4):413-21. PubMed ID: 26558399
[TBL] [Abstract][Full Text] [Related]
24. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound.
Gao WQ; Feng QZ; Li YF; Li YX; Huang Y; Chen YM; Yang B; Lu CY
BMC Cardiovasc Disord; 2014 May; 14():60. PubMed ID: 24886532
[TBL] [Abstract][Full Text] [Related]
25. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
Muhlestein JB; Lappé DL; Lima JA; Rosen BD; May HT; Knight S; Bluemke DA; Towner SR; Le V; Bair TL; Vavere AL; Anderson JL
JAMA; 2014 Dec; 312(21):2234-43. PubMed ID: 25402757
[TBL] [Abstract][Full Text] [Related]
26. Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy: long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study, a prospective large-scale observational cohort study.
Itakura H; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K;
Circ J; 2008 Aug; 72(8):1218-24. PubMed ID: 18654003
[TBL] [Abstract][Full Text] [Related]
27. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Shah SJ; Waters DD; Barter P; Kastelein JJ; Shepherd J; Wenger NK; DeMicco DA; Breazna A; LaRosa JC
J Am Coll Cardiol; 2008 May; 51(20):1938-43. PubMed ID: 18482661
[TBL] [Abstract][Full Text] [Related]
28. [Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Arntz HR; Wunderlich W; Schnitzer L; Stern R; Fischer F; Agrawal R; Linderer T; Schultheiss HP
Z Kardiol; 1999 Aug; 88(8):582-90. PubMed ID: 10506395
[TBL] [Abstract][Full Text] [Related]
29. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.
Teramoto T; Nakaya N; Yokoyama S; Ohashi Y; Mizuno K; Nakamura H;
J Atheroscler Thromb; 2010 Aug; 17(8):879-87. PubMed ID: 20543522
[TBL] [Abstract][Full Text] [Related]
30. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
Hunninghake DB
Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
[TBL] [Abstract][Full Text] [Related]
32. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL.
Li C; Chen Q; Zhang M; Liu Y; Chu Y; Meng F; Wang J; Tang J; Luo J; Niu X; Wei M
BMC Cardiovasc Disord; 2021 Jan; 21(1):41. PubMed ID: 33468066
[TBL] [Abstract][Full Text] [Related]
33. Optimal cutoff value of high-density lipoprotein cholesterol for predicting coronary artery disease in Taiwanese population.
Huang YC; Ho CC; Lin PT; Lee BJ; Lai CH; Liaw YP
Nutr Res; 2010 Jan; 30(1):21-6. PubMed ID: 20116656
[TBL] [Abstract][Full Text] [Related]
34. Impact of intensively lowered low-density lipoprotein cholesterol on deferred lesion prognosis.
Nakamura S; Yamamoto T; Teng Y; Matsumoto S; Kasano K; Yoshiwara H; Hattori E; Tokunaga T; Yonetsu T; Hirao K
Catheter Cardiovasc Interv; 2020 Mar; 95(4):E100-E107. PubMed ID: 31140709
[TBL] [Abstract][Full Text] [Related]
35. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan.
Ho LT; Yin WH; Chuang SY; Tseng WK; Wu YW; Hsieh IC; Lin TH; Li YH; Huang LC; Wang KY; Ueng KC; Fang CC; Pan WH; Yeh HI; Wu CC; Chen JW;
PLoS One; 2015; 10(3):e0116513. PubMed ID: 25756522
[TBL] [Abstract][Full Text] [Related]
36. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia.
Matsuzaki M; Kita T; Mabuchi H; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2002 Dec; 66(12):1087-95. PubMed ID: 12499611
[TBL] [Abstract][Full Text] [Related]
37. Is "strict" conventional therapy enough for the treatment of coronary artery disease?
Sakata Y
Circ J; 2011; 75(9):2046-7. PubMed ID: 21836368
[No Abstract] [Full Text] [Related]
38. [Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia].
Baller D; Gleichmann U; Notohamiprodjo G; Weise R; Holzinger J; Montanus H; Betker S; Lehmann J
Z Kardiol; 1998; 87 Suppl 2():136-44. PubMed ID: 9827472
[TBL] [Abstract][Full Text] [Related]
39. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
40. Relationship between LDL-C reduction after coronary revascularization and prevention of recurrence of cardiovascular events.
Nishiwaki T; Kishi D; Yoshie F; Fukuda K; Ibuki C; Seino Y; Satoh M
J Pharm Pharm Sci; 2010; 13(2):254-62. PubMed ID: 20816010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
